Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Curtis Schalit

Dentist, Oral and Maxillofacial Surgery Daytona Beach, FL Doctor of Dentistry

NPI 1730112749 CMS profile 168655

549 Health Blvd, Daytona Beach, FL 32114

Open in the dashboard

General payments

$333,076

431 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Curtis Schalit of Daytona Beach, FL is reported in the CMS Open Payments database as having received $333,076 across 431 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Dentist, Oral and Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55,988 71
2024 General $47,780 70
2023 General $84,491 88
2022 General $91,881 66
2021 General $13,012 30
2020 General $28,064 43
2019 General $11,860 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Curtis Schalit
  • Dentist, Oral and Maxillofacial Surgery median
  • Middle half of Dentist, Oral and Maxillofacial Surgery
  • National median

In program year 2025, general payments to Curtis Schalit were reported at $55,988. Among 3,834 Dentist, Oral and Maxillofacial Surgery profiles paid that year, the median was $150 and the middle half received between $56 and $423.

Show as a table
Year Curtis Schalit Dentist, Oral and Maxillofacial Surgery median Middle half National median
2019 $11,860 $142 $50–$420 $163
2020 $28,064 $96 $36–$277 $114
2021 $13,012 $138 $45–$419 $132
2022 $91,881 $144 $48–$367 $149
2023 $84,491 $153 $55–$399 $160
2024 $47,780 $152 $50–$400 $164
2025 $55,988 $150 $56–$423 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $188,240 228 payments
  2. Allergan Inc. $143,727 173 payments
  3. Merz North America, Inc. $555 10 payments
  4. Zimmer Biomet Holdings, Inc. $406 15 payments
  5. BioHorizons Implant Systems Inc. $80 1 payment
  6. Nobel Biocare USA $28 1 payment
  7. Solta Medical, a division of Bausch Health US, LLC $19 1 payment
  8. Zimvie Inc. $13 1 payment
  9. KLS-Martin L.P. $9 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $284,994 109 payments
  2. Consulting Fee $27,636 12 payments
  3. Travel and Lodging $11,166 30 payments
  4. Food and Beverage $9,280 280 payments
Products named General payments · program years 2019–2025
  1. BOTOX $100,156 119 payments
  2. BOTOX COSMETIC $28,094 60 payments
  3. KYBELLA $1,950 1 payment
  4. Traumaone $172 3 payments
  5. BIOHORIZONS Implant Dentistry $80 1 payment
  6. BIOHORIZONS Implant Dentistry $80 1 payment
  7. BIOHORIZONS Implant Dentistry $80 1 payment
  8. BIOHORIZONS Implant Dentistry $80 1 payment
  9. BIOHORIZONS Implant Dentistry $80 1 payment
  10. Diem2 $56 4 payments
  11. Other $209 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

324

Median for Maxillofacial Surgery: 343

Drug cost

$1,613

Median for Maxillofacial Surgery: $1,437

Branded share of claims

38%

Median for Maxillofacial Surgery: 21.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 14 $527
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 72 $339
Ibuprofen Generic 85 $232
Acyclovir Generic 38 $201
Ondansetron Odt Ondansetron Brand 37 $131
Alprazolam Generic 54 $109
Chlorhexidine Gluconate Generic 12 $59
Amoxicillin Generic 12 $14

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 692 Part D prescribers listed as Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$2,336

Medicare's payments for the services billed

Medicare patients

13

Average age 75

Services billed

23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $24,910
$24,910 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

431 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record